---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-068604"
form_type: "8-K"
ticker: "NXTC"
cik: "0001661059"
company_name: "NextCure, Inc."
filed_at: "2026-06-01T12:10:58+00:00"
generated_at: "2026-06-01T12:15:27.372596+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NextCure Phase 1 SIM0505 data: 55% ORR in gynecologic cancers; cash into Q1 2027

## Summary
- ORR of 55% (11/20) in gynecologic cancers at 4.8-8.0 mg/kg with ≥12 wks follow-up; 52.9% in ovarian, 66.7% in USC.
- TEAEs leading to dose discontinuation in 3 patients (Gr2 ILD, Gr3 fungal pneumonia, Gr4 thrombocytopenia); no primary prophylaxis for hematologic toxicities used.
- Patients heavily pretreated: median 5 prior systemic regimens (range 1-12); 78% ovarian cancer.
- Cash, cash equivalents and marketable securities expected to fund operations into Q1 2027.
- Virtual KOL event scheduled for June 2, 2026 at 8 AM ET.

## SEC filing metadata
- accession: 0001104659-26-068604
- form_type: 8-K
- ticker: NXTC
- cik: 0001661059
- company_name: NextCure, Inc.
- filed_at: 2026-06-01T12:10:58+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661059/000110465926068604/0001104659-26-068604-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661059/000110465926068604/nxtc-20260601x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-068604
- JSON: https://secwatch.observer/filing/0001104659-26-068604.json
- Plain text: https://secwatch.observer/filing/0001104659-26-068604.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.